These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

738 related items for PubMed ID: 22339676

  • 1. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W, Chen J, Chuang M, Jiang D.
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
    Feng N, Luo J, Guo X.
    Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Multiple myeloma cell line U266 apoptosis induced by velcade].
    Chen LJ, Li JY, Qian SX, Zhu GR, Zheng WJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):696-9. PubMed ID: 16928302
    [Abstract] [Full Text] [Related]

  • 10. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y, Yan H, Frost P, Gera J, Lichtenstein A.
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [Abstract] [Full Text] [Related]

  • 11. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
    Zhang H, Chen J, Zeng Z, Que W, Zhou L.
    Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
    Guan M, Zhu L, Somlo G, Hughes A, Zhou B, Yen Y.
    Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of multiple myeloma cell proliferation by ginsenoside Rg3 via reduction in the secretion of IGF-1.
    Li Y, Yang T, Li J, Hao HL, Wang SY, Yang J, Luo JM.
    Mol Med Rep; 2016 Sep; 14(3):2222-30. PubMed ID: 27430248
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
    Morelli MB, Offidani M, Alesiani F, Discepoli G, Liberati S, Olivieri A, Santoni M, Santoni G, Leoni P, Nabissi M.
    Int J Cancer; 2014 Jun 01; 134(11):2534-46. PubMed ID: 24293211
    [Abstract] [Full Text] [Related]

  • 17. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
    He W, Fu Y, Zheng Y, Wang X, Liu B, Zeng J.
    BMC Cancer; 2021 Feb 06; 21(1):125. PubMed ID: 33549034
    [Abstract] [Full Text] [Related]

  • 18. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC.
    Cancer Res; 2005 Sep 15; 65(18):8350-8. PubMed ID: 16166312
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
    Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Martí RM.
    Int J Cancer; 2012 Feb 15; 130(4):967-78. PubMed ID: 21445974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.